NCT04469075

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.

Conditions

• Glioblastoma
• Recurrent Glioblastoma
• Skin Toxicity

Interventions

Type	Name	Description
DRUG	Clindamycin Phosphate	phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)
DRUG	Triamcinolone Acetonide	triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change

Timeline

• Start date: 2020-07-09
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2020-07-13
• Last updated: 2025-08-08

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated drug study